The International Society of RNA Nanotechnology and Nanomedicine (ISRNN) aims to leverage recent breakthroughs in RNA nanotechnology to advance various fields, including basic sciences, medicine, and nanobiotechnology. These complex scientific endeavors necessitate interdisciplinary collaboration among researchers from diverse backgrounds, presenting opportunities for world-class teams to excel. ISRNN serves as an innovative hub facilitating global interaction and collaboration among interdisciplinary teams, fostering the development of new research collaborations and shaping the future of RNA nanoscience and nanotechnology education.

Established in 1986, the American Association of Pharmaceutical Scientists (AAPS) is a professional organization comprising approximately 7,000 individual members and over 10,000 actively involved stakeholders from academia, industry, government, and other pharmaceutical science research institutions worldwide. AAPS is committed to advancing the capacity of pharmaceutical scientists to develop products and therapies that enhance global health.

The European Federation for Pharmaceutical Sciences (EUFEPS) serves as a pivotal organization uniquely representing scientists engaged in drug research, development, regulation, and policy-making across Europe. With its inclusive membership encompassing nearly 15,000 professionals from academia, industry, government, and other institutions, EUFEPS is committed to fostering collaboration and excellence in pharmaceutical sciences throughout the continent. By providing a dynamic platform for learning, growth, and idea-sharing, EUFEPS empowers its members to make meaningful contributions that have a lasting impact on global health and well-being. Whether you are an individual researcher, part of a national society, or affiliated with other professional groups, EUFEPS invites those with scientific curiosity and a visionary outlook to join its diverse community and help shape the future of pharmaceutical research.

The Controlled Release Society (CRS) is the premier global community for experts in delivery science, encompassing researchers, engineers, clinicians, and technical professionals dedicated to advancing drug delivery technologies. Through fundamental research, regulatory science, and clinical translation, CRS members shape the future of delivery science and technology, as evidenced by the wealth of knowledge shared in CRS journals and at the Annual Meeting & Exposition. By fostering interdisciplinary networking opportunities and providing avenues for career advancement, CRS empowers its members to make meaningful contributions to the field while advancing their professional growth.

The Nanotechnology Characterization Laboratory (NCL), established by the National Cancer Institute (NCI), expedites nanomedicine progress by conducting preclinical characterization and safety testing of nanoparticles. A collaborative effort involving the NCI, the US Food and Drug Administration (FDA), and the National Institute of Standards and Technology (NIST), the NCL serves as a vital resource for cancer researchers across academia, industry, and government. It offers expertise in characterizing nanotechnologies for cancer therapeutics and diagnostics, including evaluating novel platforms, addressing side effects, and advancing cancer nanotechnology knowledge. Additionally, recognizing the significance of nanoparticles in combating the COVID-19 pandemic, the NCL supports the characterization of nanotechnology-based COVID vaccines and therapeutics.

The National Nanotechnology Initiative (NNI) envisions a future where the understanding and manipulation of matter at the nanoscale drive continuous technological and industrial revolutions for the betterment of society. As a collaborative effort among over thirty Federal departments, independent agencies, and commissions, the NNI promotes interagency coordination, shared infrastructure, and resource leveraging to advance nanotechnology research and development. By establishing common goals, priorities, and strategies that align with agency-specific missions, the NNI fosters innovation and progress in nanotechnology across various sectors.

The International Association of Nanotechnology (IANT) is a non-profit organization dedicated to advancing scientific research and business development in the fields of Nanoscience and Nanotechnology for societal benefit. Emphasizing friendship, equality, and cooperation among members globally, IANT focuses on responsible technology use and opposes any destructive applications. With initiatives spanning advanced R&D, intellectual property, safety regulations, and societal impacts, IANT works on a global scale to foster collaboration, education, economic development, and regulatory policies in Nanotechnology. Offering membership benefits such as networking opportunities, participation in subcommittees, discounts on events and publications, and professional recognition, IANT invites individuals to join and contribute to the advancement of Nanotechnology. As organizers of regional meetings and the International Congress of Nanotechnology, IANT and its affiliates provide platforms for clarity and progress in Nanotechnology research, development, and ethical considerations.

The NanoDDS organizing committee is excited to announce a virtual meeting. Join scientists from academia and industry for lectures from distinguished speakers. Registration is now open and free. Attendees can look forward to discussions on topics such as next-generation nanotherapeutics, global health initiatives, COVID vaccine development, and leadership challenges in promoting diversity, equity, and inclusion in nanomedicine research. This symposium is ideal for pharmaceutical industry scientists, graduate students, and academics interested in exploring the potential of nanotechnology and other exciting advancements. Visit the NanoDDS website for more information about this symposium and for past symposiums.

Nano Pharmaceuticals presents an unparalleled opportunity for researchers, industry professionals, and enthusiasts to delve into the forefront of Pharmaceutical Nanotechnology and Nanomedicine. This pivotal event serves as a nexus for the exchange of groundbreaking ideas, innovations, and technologies that are shaping the future of medicine. Attendees will gain insights into the transformative potential of nanomedicine in revolutionizing healthcare delivery and treatment modalities. From exploring novel drug delivery vehicles to targeted therapies, Nano Pharmaceuticals promises to be a cornerstone event for those at the forefront of advancing pharmaceutical science.